MiMedx Group

MDXG

Marietta, United States· Est. 2007

MiMedx Group leverages its proprietary PURION® processing platform to develop and commercialize regenerative tissue products derived from human placental tissue. The company's primary focus is on the advanced wound care and surgical recovery markets, with a portfolio of products designed to address unmet needs in tissue repair. As a commercial-stage entity, MiMedx has established a sales and distribution network while continuing to advance its clinical pipeline. The company's strategic direction involves expanding clinical evidence for its products and exploring new therapeutic applications for its placental tissue platform.

mimedx.com

MDXG · Stock Price

USD 4.10-3.64 (-47.03%)

Market Cap: $605.4M

Historical price data

Market Cap: $605.4MPipeline: 8 drugs (3 Phase 3)Patents: 20Founded: 2007HQ: Marietta, United States

Sector Ranking#12 in Regenerative Medicine

AI Company Overview

Wound CareSurgical Recovery

Technology Platform

Proprietary PURION® processing platform for cleansing, dehydrating, and preserving human placental tissue (amnion, chorion, umbilical cord) to create regenerative allografts for wound care and surgical applications.

Pipeline

8 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Micronized DHACM + Saline Injection	Tendonitis;Achilles	Phase 3
Saline Injection	Fasciitis, Plantar	Phase 3
Saline Injection	Fasciitis, Plantar	Phase 2/3
Micronized dHACM + Saline	Knee Osteoarthritis	Phase 2
AmnioFix®	Prostate Cancer	Phase 2

Funding History

Total raised:$80M

Debt$50MSilicon Valley BankJan 1, 2017

IPO$30MUndisclosedJan 1, 2008

Opportunities

Growth opportunities include expanding market penetration in the large diabetic foot ulcer and venous leg ulcer markets with robust clinical data, exploring new surgical applications for its placental tissue platform in orthopedics and other specialties, and leveraging its commercial infrastructure to potentially in-license or acquire complementary regenerative medicine assets.

Risk Factors

Key risks include evolving FDA regulations for human cell and tissue products (HCT/Ps), reimbursement challenges and pricing pressure from payers, intense competition in advanced wound care and surgical biologics, and dependence on a consistent supply of donated placental tissue.

Historical legal and governance issues also present an ongoing risk factor.

Competitive Landscape

MiMedx competes with other placental tissue processors (e.g., Organogenesis, StimLabs), providers of advanced wound care biologics and synthetics (e.g., 3M, Smith & Nephew), and companies offering surgical regenerative products (e.g., Baxter, Integra). Its differentiation is based on its PURION® processed placental tissue portfolio and its focus on generating clinical evidence across multiple indications.